Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808

J Alzheimers Dis. 2014;38(1):171-84. doi: 10.3233/JAD-130098.


Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have recently reported early clinical results of a novel PHF-tau targeting PET imaging agent, [F18]-T807. Since then, we have investigated a second novel PHF-tau targeting PET imaging agent, [F18]-T808, with different pharmacokinetic characteristics, which may be favorable for imaging Alzheimer's disease and other tauopathies. Here, we describe the first human brain images with [F18]-T808.

Keywords: Alzheimer's disease; PHF-tau; amyloid-β; brain imaging; mild cognitive impairment; molecular imaging; neurofibrillary tangles; tau; tau aggregates; tauopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnostic imaging*
  • Benzimidazoles* / pharmacokinetics
  • Brain / diagnostic imaging*
  • Brain / drug effects
  • Brain / metabolism*
  • Brain Mapping
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Mental Status Schedule
  • Middle Aged
  • Positron-Emission Tomography
  • Pyrimidines* / pharmacokinetics
  • Time Factors
  • tau Proteins / metabolism*


  • Benzimidazoles
  • Pyrimidines
  • T808 compound
  • tau Proteins
  • Fluorodeoxyglucose F18